Abstract
Chronic inflammatory demyelinating polyneuropathy with anti-myelin associated glycoprotein antibodies represents a small subgroup of patients for whom management may not be straightforward. A recent study offers insight into this issue, with results suggesting priority should be given to the clinical phenotype.
| Original language | English |
|---|---|
| Pages (from-to) | 301-302 |
| Journal | European Journal of Neurology |
| Volume | 30 |
| Issue number | 2 |
| Early online date | 21 Nov 2022 |
| DOIs | |
| Publication status | Published - Feb 2023 |
Keywords
- Neurology (clinical)
- Neurology
Fingerprint
Dive into the research topics of 'Chronic inflammatory demyelinating polyneuropathy with positive anti-myelin associated glycoprotein antibodies: back to clinical basics'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver